The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up.
Disease activity
Disease relapse
Interleukin-6
Takayasu arteritis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
15
01
2020
accepted:
23
03
2020
revised:
16
03
2020
pubmed:
11
5
2020
medline:
15
5
2021
entrez:
11
5
2020
Statut:
ppublish
Résumé
To evaluate the value of interleukin-6 (IL-6) in predicting long-term disease prognosis for Takayasu arteritis (TA). Sixty-seven TA patients, who had IL-6 levels detected at the first visit and had a regular follow-up of at least 2 years, were enrolled. Data recorded up to March 31, 2019, including clinical presentations, laboratory indices, treatments, and radiological images were collected and used for analysis. The value of IL-6 in predicting disease relapse and imaging progression was analyzed. IL-6 levels were positively related with disease activity index, including Kerr scores, C-reactive protein (CRP) levels. Patients were divided into three groups according to baseline serum IL-6 levels: low group (< 5.4 pg/mL, n = 29), medium group (5.4-11.5 pg/mL, n = 20), and high group (> 11.5 ng/mL, n = 18). Patients in the medium and high group had higher disease activity than those in the low group (p < 0.01). Baseline IL-6 levels were correlated with luminal stenosis (p < 0.05), although no significant correlations with long-term imaging progression were observed. Patients with more than 2 episodes of disease relapses were most commonly seen in the medium group (p < 0.05). Multivariate Cox proportional hazard regression analysis indicated that medium and high IL-6 levels were positive predictors for disease relapse (HR 4.3, 95%CI 1.3-18.7 p = 0.07 for medium group; HR 2.1, 95% CI 0.7-48.9, p = 0.19 for high group) with disease status and treatment adjusted. IL-6 may be a valuable predictor of TA disease relapse during long-term follow-up. Treatments targeted at IL-6 pathways might reduce disease relapse and have better prognostic effects for TA. Key Points • Positive relationships between IL-6 levels and disease activity index, including Kerr scores, C-reactive protein (CRP) levels, etc. were indicated. • Medium and high baseline IL-6 levels were valuable for predicting disease relapse during the 2-year follow-up. • Baseline IL-6 levels were positively correlated with luminal stenosis on imaging.
Identifiants
pubmed: 32388749
doi: 10.1007/s10067-020-05066-8
pii: 10.1007/s10067-020-05066-8
doi:
Substances chimiques
Interleukin-6
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3417-3425Subventions
Organisme : National Natural Science Foundation of China
ID : 81601398
Organisme : National Natural Science Foundation of China
ID : 81771730
Organisme : National Natural Science Foundation of China
ID : 81801598
Références
Yang L, Zhang H, Jiang X, Zou Y, Qin F, Song L, Guan T, Wu H, Xu L, Liu Y, Zhou X, Bian J, Hui R, Zheng D (2014) Clinical manifestations and long-term outcome for patients with Takayasu arteritis in China. J Rheumatol 41:2439–2446
doi: 10.3899/jrheum.140664
Yilmaz N, Can M, Oner FA, Kalfa M, Emmungil H, Karadag O, Yildiz F, Kimyon G, Yilmazer B, Gerdan V, Bilge SY, Ilhan B, Cobankara V, Kasifoglu T, Cefle A, Kisacik B, Onat AM, Akar S, Onen F, Erken E, Kiraz S, Aksu K, Keser G, Mumcu G, Direskeneli H (2013) Impaired quality of life, disability and mental health in Takayasu’s arteritis. Rheumatology (Oxford) 52:1898–1904
doi: 10.1093/rheumatology/ket238
Watanabe Y, Miyata T, Tanemoto K (2015) Current clinical features of new patients with Takayasu arteritis observed from a cross-country research in Japan: age and sex specificity. Circulation 132:1701–1709
doi: 10.1161/CIRCULATIONAHA.114.012547
Kerr FS, Hallahan CW, Gordano J et al (1994) Takayasu arteritis. Ann Intern Med 120:919–929
doi: 10.7326/0003-4819-120-11-199406010-00004
Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, Jeyaseelan L, Lawrence A, Bacon PA, Indian Rheumatology Vasculitis (IRAVAS) group (2013) Development and initial validation of the Indian Takayasu clinical activity score (ITAS2010). Rheumatology (Oxford) 52:1795–1801
doi: 10.1093/rheumatology/ket128
Alibaz-Oner F, Aydin SZ, Akar S, Aksu K, Kamali S, Yucel E, Karadag O, Ozer H, Kiraz S, Onen F, Inanc M, Keser G, Akkoc N, Direskeneli H (2015) Assessment of patients with Takayasu arteritis in routine practice with Indian Takayasu clinical activity score. J Rheumatol 42:1443–1447
doi: 10.3899/jrheum.140817
Ma LY, Li CL, Ma LL et al (2019) Value of contrast-enhanced ultrasonography of the carotid artery for evaluating disease activity in Takayasu arteritis. Arthritis Res Ther 21:24
doi: 10.1186/s13075-019-1813-2
Chung JW, Kim HC, Choi YH, Kim SJ, Lee W, Park JH (2007) Patterns of aortic involvement in Takayasu arteritis and its clinical implications: evaluation with spiral computed tomography angiography. J Vasc Surg 45:906–914
doi: 10.1016/j.jvs.2007.01.016
Jiang L, Li D, Yan F, Dai X, Li Y, Ma L (2012) Evaluation of Takayasu arteritis activity by delayed contrast-enhanced magnetic resonance imaging. Int J Cardiol 155:262–267
doi: 10.1016/j.ijcard.2010.10.002
Germano G, Monti S, Ponte C et al (2017) The role of ultrasound in the diagnosis and follow-up of large-vessel vasculitis: an update. Clin Exp Rheumatol 35(Suppl):194–198
pubmed: 28375834
Zhang X, Zhou J, Sun Y, Shi H, Ji Z, Jiang L (2018)
doi: 10.1007/s10067-017-3960-7
Tamura N, Maejima Y, Tezuka D, Takamura C, Yoshikawa S, Ashikaga T, Hirao K, Isobe M (2017) Profiles of serum cytokine levels in Takayasu arteritis patients: potential utility as biomarkers for monitoring disease activity. J Cardiol 70:278–285
doi: 10.1016/j.jjcc.2016.10.016
Sun Y, Ma L, Yan F, Liu H, Ding Y, Hou J, Jiang L (2012) MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu’s arteritis. Int J Cardiol 156:236–238
doi: 10.1016/j.ijcard.2012.01.035
Matsuyama A, Sakai N, Ishigami M, Hiraoka H, Kashine S, Hirata A, Nakamura T, Yamashita S, Matsuzawa Y (2003) Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation 108:1469–1473
doi: 10.1161/01.CIR.0000090689.69973.B1
Ishihara T, Haraguchi G, Kamiishi T, Tezuka D, Inagaki H, Isobe M (2011) Sensitive assessment of activity of Takayasu's arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol 57:1712–1713
doi: 10.1016/j.jacc.2010.10.058
Alibaz-Oner F, Aksu K, Yentur SP, Keser G, Saruhan-Direskeneli G, Direskeneli H (2016) Plasma pentraxin-3 levels in patients with Takayasu’s arteritis during routine follow-up. Clin Exp Rheumatol 34:s73–s76
pubmed: 26885720
Kong X, Sun Y, Ma L, Chen H, Wei L, Wu W, Ji Z, Ma L, Zhang Z, Zhang Z, Zhao Z, Hou J, Dai S, Yang C, Jiang L (2016) The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol 34:S21–S27
pubmed: 26633132
Gao Q, Lv N, Dang A et al (2019) Association of interleukin-6 and interleukin-10 expression, gene polymorphisms, and Takayasu arteritis in a Chinese Han population. Clin Rheumatol 38:143–148
doi: 10.1007/s10067-018-4260-6
Alibaz-Oner F, Yentur SP, Saruhan-Direskeneli G et al (2015) Serum cytokine profiles in Takayasu’s arteritis: search for biomarkers. Clin Exp Rheumatol 33:S 32–S 35
Pulsatelli L, Boiardi L, Assirelli E et al (2017) Interleukin-6 and soluble interleukin-6 receptor are elevated in larger-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol 103:102–110
Kong X, Ma L, Ji Z, Dong Z, Zhang Z, Hou J, Zhang S, Ma L, Jiang L (2018) Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis. Clin Exp Rheumatol 36:62–72
pubmed: 28770707
Chen R, Sun Y, Cui X, Ji Z, Kong X, Wu S, Huang Q, Dai X, Zhang S, Ma L, Jiang L (2019) Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu’s arteritis. J Autoimmun 99:39–47
doi: 10.1016/j.jaut.2019.01.010
Arend WP, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134
doi: 10.1002/art.1780330811
Hata A, Noda M, Moriwaki R et al (1996) Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 54:155–163
doi: 10.1016/S0167-5273(96)02813-6
Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y (2014) Targeting interleukin-6 in inflammatory autoimmune disease and cancers. Pharmacol Ther 141:125–139
doi: 10.1016/j.pharmthera.2013.09.004
Manku S, Wong W, Luo Z, Seidman MA, Alabdurubalnabi Z, Rey K, Enns W, Avina-Zubieta JA, Shojania K, Choy JC (2018) IL-6 expression is correlated with increased T-cell proliferation and survival in the arterial wall in giant cell arteritis. Cardiovasc Pathol 33:55–61
doi: 10.1016/j.carpath.2018.01.004
Burja B, Feichtinger J, Lakota K, Thallinger GG, Sodin-Semrl S, Kuret T, Rotar Ž, Ješe R, Žigon P, Čučnik S, Mali P, Praprotnik S, Tomšič M, Hočevar A (2019) Utility of serological biomarkers for giant cell arteritis in a large cohort treatment-naïve patients. Clin Rheumatol 38:317–329
doi: 10.1007/s10067-018-4240-x
Kong X, Zhang X, Lv P et al (2018) Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide. Int J Cardiol 266:222–228
doi: 10.1016/j.ijcard.2017.12.066
Sun Y, Ma L, Kong X et al (2017) Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu’s arteritis. Rheumatol Int 37:2019–2026
doi: 10.1007/s00296-017-3847-6
van Sleen Y, Sandovici M, Abdulahad WH et al (2019) Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kez034
Yoshifuji H (2019) Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy. Mod Rheumatol 29:287–293
doi: 10.1080/14397595.2018.1546358
Koster MJ, Warrington KJ (2017) Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. BMC Rheumatol 1:2
doi: 10.1186/s41927-017-0004-5
Low C, Conway R (2019) Current advances in the treatment of giant cell arteritis: the role of biologics. Ther Adv Musculoskelet Dis. https://doi.org/10.1177/1759720X19827222
Adler S, Reichenbach S, Gloor A et al (2019) Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxford) 58:1939–1643
doi: 10.1093/rheumatology/kez091
Sun Y, Kong X, Wu S, Ma L, Yan Y, Lv P, Jiang L (2019) YKL-40 as a new biomarker of disease activity in Takayasu arteritis. Int J Cardiol 293:231–237
doi: 10.1016/j.ijcard.2019.06.058
Loricera J, Bianco R, Hernandez JL et al (2016) Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol 34:S44–S53
pubmed: 27050507
Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, Constans J, Alric L, Jego P, Busato F, Cabon M, Dhote R, Estibaliz L, Koné-Paut I, Landron C, Lavigne C, Lioger B, Michaud M, Ruivard M, Sacre K, Gottenberg JE, Gaches F, Goulenok T, Salvarani C, Cacoub P, Fain O, Saadoun D, French Takayasu network (2018) Efficacy of tocilizumab in Takayasu arteritis: multicenter retrospective study of 46 patients. J Autoimmun 91:55–60
doi: 10.1016/j.jaut.2018.04.002